35979-69-2

Usage

Uses

Used in Pharmaceutical Industry:
4-BroMo-2-Methylbutan-2-ol is used as a reagent for the preparation of vitamin D3 analogues, which are essential for maintaining healthy bone metabolism, immune system function, and cellular differentiation. Its role in the synthesis of these analogues is crucial for the development of pharmaceuticals that can address various health conditions related to vitamin D deficiency or imbalance.
As a chemical intermediate, 4-BroMo-2-Methylbutan-2-ol can also be utilized in the synthesis of other complex organic compounds, further expanding its applications in the chemical and pharmaceutical industries. Its unique properties, such as being a brominated tertiary alcohol, make it a valuable building block for the development of new drugs and other chemical products.

Upstream product

• 539-74-2 Ethyl 3-bromopropionate 
• 75-16-1 methylmagnesium bromide 
• 107-82-4 i-pentyl bromide 
• 917-64-6 methyl magnesium iodide 
• 3395-91-3 Methyl 3-bromopropionate 
• 15486-96-1 3-Bromopropionyl chloride 
• 74-88-4 methyl iodide 
• 67883-17-4 1-bromo-3-methyl-3-trimethyl-silyloxybutane 
• 17689-66-6 3-hydroxy-3-methylbutyl toluene-4-sulfonate 
• 2568-33-4 3-methyl-butane-1,3-diol 

Downstream Products

• 6245-99-4 2,2-dimethyl-oxetane 
• 139619-73-1 (1R,3S)-5-[2-[(1R,3aS,6S,7aR)-6-(3,3-Dimethoxy-propyl)-1-((R)-5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-4-methylene-cyclohexane-1,3-diol 
• 194208-59-8 2-{2-[(3R,3aR,5R,7aR)-7-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methyl-cyclohex-1-enylethynyl]-3-((R)-5-methoxymethoxy-1,5-dimethyl-hexyl)-3a-methyl-2,3,3a,4,5,7a-hexahydro-1H-inden-5-yl]-ethyl}-[1,3]dioxolane 
• 139619-83-3 2-{2-[(3R,3aR,5S,7aS)-7-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-3-((R)-5-methoxymethoxy-1,5-dimethyl-hexyl)-3a-methyl-octahydro-inden-5-yl]-ethyl}-[1,3]dioxolane 
• 83872-56-4 1-phenylsulphonyl-3-methyl-3-hydroxybutane 
• 2170751-30-9 5,5-dimethyl-3-nitro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine 
• 2170752-31-3 5,5-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-amine 
• 2676862-34-1 5,5-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine 
• 91967-95-2 2-methyl-4-(phenylthio)-2-butanol 
• 1430724-43-8 N-(3-(5-(1-(3-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)ethanesulfonamide 
• 1430728-05-4 4-(4-(1-(3-amino-5-(1H-pyrrol-1-yl)phenyl)-1H-benzo[d]imidazol-5-yl)-1H-1,2,3-triazol-1-yl)-2-methylbutan-2-ol 
• 1430724-42-7 N-(3-(5-(1-(3-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)acetamide 

Relevant academic research and scientific papers

Structure-activity relationships for side chain oxysterol agonists of the hedgehog signaling pathway

Oxysterols (OHCs) are byproducts of cholesterol oxidation that are known to activate the Hedeghog (Hh) signaling pathway. While OHCs that incorporate hydroxyl groups throughout the scaffold are known, those that act as agonists of Hh signaling primarily contain a single hydroxyl on the alkyl side chain. We sought to further explore how side chain hydroxylation patterns affect oxysterol-mediated Hh activation, by performing a structure-activity relationship study on a series of synthetic OHCs. The most active analogue, 23(R)-OHC (35), demonstrated potent activation of Hh signaling in two Hh-dependent cell lines (EC50 values 0.54-0.65 μM). In addition, OHC 35 was approximately 3-fold selective for the Hh pathway as compared to the liver X receptor, a nuclear receptor that is also activated by endogenous OHCs. Finally, 35 induced osteogenic differentiation and osteoblast formation in cultured cells, indicating functional agonism of the Hh pathway.

An efficient synthesis of the 25-hydroxy Windaus-Grundmann ketone

A short and efficient synthesis of the 25-hydroxy Windaus-Grundmann ketone from the Inhoffen-Lythgoe diol is described (seven steps, 70% overall). The most relevant feature of the synthesis is the preparation of the Wittig reagent 3 from cheap and commerc

Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy

Chemotherapy-induced neurotoxicity is a common adverse effect of cancer treatment. No medication has been shown to be effective in the prevention or treatment of chemotherapy-induced neurotoxicity. Using minoxidil as an initial template for structural modifications in conjunction with an in vitro neurite outgrowth assay, an image-based high-content screening platform, and mouse behavior models, an effective neuroprotective agent CN016 was discovered. Our results showed that CN016 could inhibit paclitaxel-induced inflammatory responses and infiltration of immune cells into sensory neurons significantly. Thus, the suppression of proinflammatory factors elucidates, in part, the mechanism of action of CN016 on alleviating paclitaxel-induced peripheral neuropathy. Based on excellent efficacy in improving behavioral functions, high safety profiles (MTD > 500 mg/kg), and a large therapeutic window (MTD/MED > 50) in mice, CN016 might have great potential to become a peripherally neuroprotective agent to prevent neurotoxicity caused by chemotherapeutics as typified by paclitaxel.

Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment

In a pancreatic tumor microenvironment, activated pancreatic stellate cells (PSCs) produce extracellular matrix (ECM) to form a barrier to drug penetration. Moreover, the interaction between cancer cells and activated PSCs promotes the tumor growth. Vitam

Efficient salt-induced kinase inhibitor and preparation method thereof

The invention discloses an efficient salt-induced kinase inhibitor and a preparation method thereof, and the efficient salt-induced kinase inhibitor is characterized by comprising substances of a chemical formula in the invention. The salt-induced kinase inhibitor with excellent performance has high inhibitory activity for in-vitro experiments and also has high cell inhibitory activity.

Ni-Catalyzed Formal Cross-Electrophile Coupling of Alcohols with Aryl Halides

Direct coupling of unactivated alcohols remains a challenge in current synthetic chemistry. We herein demonstrate a strategy building upon in situ halogenation/reductive coupling of alcohols with aryl halides to forge Csp2-Csp3 bonds. The combination of 2-chloro-3-ethylbenzo[d]oxazol-3-ium salt (CEBO) and TBAB as the mild bromination reagents enables rapid transformation of a wide range of alcohols to their bromide counterparts within one to 5 min in CH3CN and DMF, which is compatible with the Ni-catalyzed cross-electrophile coupling conditions in the presence of a chemical reductant. The present method is suitable for arylation of a myriad of structurally complex alcohols with no need for prepreparation of alkyl halides. More importantly, the mild and kinetically rapid bromination process has shown good selectivity in the bromination/arylation of symmetric diols and less sterically hindered hydroxyl groups in polyols, thus offering promise for selective functionalization of diols and polyols without laborious protecting/deprotecting operations. The practicality of this work is also evident in the arylation of a number of carbohydrates, drug compounds, and naturally occurring alcohols.

Preparation method of a 25-hydroxy vitamin D3 intermediate

The invention discloses a preparation method of a 25-hydroxy vitamin D3 intermediate, wherein the 25-hydroxy vitamin D3 intermediate is 2-methyl-4-(phenylsulfonyl)-2-butanol, and is prepared from 3-methyl-3-butanol-p-toluenesulfonate, a halide and sodium

Efficient synthesis of 3-TBDMS-11α,25-dihydroxyvitamin D3 and D2 ethers

Vitamin D deficiency might cause a wide variety of human disorders. As a prerequisite for appropriate diagnosis and therapy, medicinally relevant vitamin D metabolites have to be assayed most accurately and with high specificity. It has been demonstrated, that vitamin D conjugates, linked via a hydroxyl group at C11, might be promising for the development of highly specific antibodies to be employed in competitive protein binding assays. The connective synthesis of 3-TBDMS-11α,25-dihydroxyvitamin D3 and D2 ethers in 500 mg scale, starting from vitamin D2, is described. For installation of a hydroxyl group at C11 a sequence of Pd(OAc)2 mediated oxidation of an enone, epoxidation and subsequent epoxide ring opening was applied to obtain a suitable CD-ring precursor, that was connected with an A-ring diphenylphosphine oxide by Wittig-Horner reaction. Finally, an appropriate side chain was installed, respectively.

CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION

The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.